Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation
The COLT trial is an investigator-driven, multicenter, non-randomized, open-label, controlled, prospective, parallel trial, aimed at assessing the efficacy (in terms of overall survival: OS) of liver transplantation (LT) in liver-only CRC metastases, compared with a matched cohort of patients bearing the same tumor characteristics, collected during the same time period and included in a phase III Italian RCT on triplet chemotherapy+antiEGFR
Liver Metastases|Colorectal Cancer Metastatic|Liver Neoplasm|Neoplasms
PROCEDURE: Liver transplant|DRUG: Chemotherapy|DRUG: Chemotherapy
Overall Survival, Time from enrolement to either death or censoring, 5 years
Progression Free Survival, Time from enrolement to either progression or censoring, 5 years|Complications rate, Complications according to Dindo Clavien Classification, 90 days after liver transplant
The COLT trial is an investigator-driven, multicenter, non-randomized, open-label, controlled, prospective, parallel trial, aimed at assessing the efficacy (in terms of overall survival: OS) of liver transplantation (LT) in liver-only CRC metastases, compared with a matched cohort of patients bearing the same tumor characteristics, collected during the same time period and included in a phase III Italian RCT on triplet chemotherapy+antiEGFR